View Item 

Show simple item record

Cost‐effectiveness analysis: cardiovascular benefits of proton pump inhibitor co‐therapy in patients using aspirin for secondary prevention
dc.contributor.authorSaini, Sameer D.en_US
dc.contributor.authorFendrick, A. Marken_US
dc.contributor.authorScheiman, James M.en_US
dc.date.accessioned2011-11-10T15:34:56Z
dc.date.available2012-09-04T15:27:40Zen_US
dc.date.issued2011-07en_US
dc.identifier.citationSaini, S. D.; Fendrick, A. M.; Scheiman, J. M. (2011). "Cost‐effectiveness analysis: cardiovascular benefits of proton pump inhibitor co‐therapy in patients using aspirin for secondary prevention." Alimentary Pharmacology & Therapeutics 34(2). <http://hdl.handle.net/2027.42/86965>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/86965
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleCost‐effectiveness analysis: cardiovascular benefits of proton pump inhibitor co‐therapy in patients using aspirin for secondary preventionen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical School, Ann Arbor, MI, USA.en_US
dc.contributor.affiliationotherCenter for Clinical Management Research, Ann Arbor VA HSR&D Center of Excellence, Ann Arbor, MI, USA.en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/86965/1/j.1365-2036.2011.04707.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2011.04707.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceSmith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363 – 72.en_US
dc.identifier.citedreferenceNewby LK, LaPointe NM, Chen AY, et al. Long‐term adherence to evidence‐based secondary prevention therapies in coronary artery disease. Circulation 2006; 113: 203 – 12.en_US
dc.identifier.citedreferenceKulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long‐term adherence with cardiovascular drug regimens. Am Heart J 2006; 151: 185 – 91.en_US
dc.identifier.citedreferenceSimpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003; 145: 438 – 44.en_US
dc.identifier.citedreferenceBiondi‐Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta‐analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667 – 74.en_US
dc.identifier.citedreferenceBurger W, Chemnitius JM, Kneissl GD, Rucker G. Low‐dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta‐analysis. J Intern Med 2005; 257: 399 – 414.en_US
dc.identifier.citedreferenceSung JJ, Lau JY, Ching JY, et al. Continuation of low‐dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152: 1 – 9.en_US
dc.identifier.citedreferencePeto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313 – 6.en_US
dc.identifier.citedreferenceCAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329 – 39.en_US
dc.identifier.citedreferenceTournoij E, Peters RJ, Langenberg M, Kanhai KJ, Moll FL. The prevalence of intolerance for low‐dose acetylsalicylacid in the secondary prevention of atherothrombosis. Eur J Vasc Endovasc Surg 2009; 37: 597 – 603.en_US
dc.identifier.citedreferenceMelloni C, Alexander KP, Ou FS, et al. Predictors of early discontinuation of evidence‐based medicine after acute coronary syndrome. The American Journal of Cardiology 2009; 104: 175 – 81.en_US
dc.identifier.citedreferenceSpiegel BM, Farid M, Dulai GS, Gralnek IM, Kanwal F. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta‐analysis. The American Journal of Medicine 2006; 119: 448 – e27.en_US
dc.identifier.citedreferenceSaini SD, Schoenfeld P, Fendrick AM, Scheiman J. Cost‐effectiveness of proton pump inhibitor cotherapy in patients taking long‐term, low‐dose aspirin for secondary cardiovascular prevention. Arch Intern Med 2008; 168: 1684 – 90.en_US
dc.identifier.citedreferenceEarnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost‐utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011; 171: 218 – 25.en_US
dc.identifier.citedreferenceLanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low‐dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Eng J Med 2000; 343: 834 – 9.en_US
dc.identifier.citedreferenceSerrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low‐dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002; 16: 1945 – 53.en_US
dc.identifier.citedreferenceDerry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta‐analysis. BMJ (Clinical research ed) 2000; 321: 1183 – 7.en_US
dc.identifier.citedreferenceLaine L. Review article: gastrointestinal bleeding with low‐dose aspirin – what’s the risk? Aliment Pharmacol Ther 2006; 24: 897 – 908.en_US
dc.identifier.citedreferenceMcQuaid KR, Laine L. Systematic review and meta‐analysis of adverse events of low‐dose aspirin and clopidogrel in randomized controlled trials. The American Journal of Medicine 2006; 119: 624 – 38.en_US
dc.identifier.citedreferenceSerebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. The American Journal of Cardiology 2005; 95: 1218 – 22.en_US
dc.identifier.citedreferenceLaine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther 2010; 32: 1240 – 8.en_US
dc.identifier.citedreferenceHernandez‐Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Medicine 2006; 4: 22.en_US
dc.identifier.citedreferenceRockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. Br Med J (Clin Res Ed) 1995; 311: 222 – 6.en_US
dc.identifier.citedreferenceRockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316 – 21.en_US
dc.identifier.citedreferenceChan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Eng J Med 2005; 352: 238 – 44.en_US
dc.identifier.citedreferenceLai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long‐term low‐dose aspirin use. N Eng J Med 2002; 346: 2033 – 8.en_US
dc.identifier.citedreferenceLanas A, Garcia‐Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti‐inflammatory drugs, antiplatelet agents, and anticoagulants. The American Journal of Gastroenterology 2007; 102: 507 – 15.en_US
dc.identifier.citedreferenceNg FH, Wong BC, Wong SY, Chen WH, Chang CM. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin‐induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re‐bleeding risk – a single‐blind, randomized controlled study. Aliment Pharmacol Ther 2004; 19: 359 – 65.en_US
dc.identifier.citedreferenceBaigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta‐analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849 – 60.en_US
dc.identifier.citedreferenceD’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139: 272 – 81.en_US
dc.identifier.citedreferenceGlynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction. The Physicians’ Health Study. Arch Intern Med 1994; 154: 2649 – 57.en_US
dc.identifier.citedreferenceSud A, Kline‐Rogers EM, Eagle KA, et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother 2005; 39: 1792 – 7.en_US
dc.identifier.citedreferenceNewby LK, Bhapkar MV, White HD, et al. Aspirin use post‐acute coronary syndromes: intolerance, bleeding and discontinuation. J Thromb Thrombolysis 2003; 16: 119 – 28.en_US
dc.identifier.citedreferencede Gaetano G. Low‐dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89 – 95.en_US
dc.identifier.citedreferencePradhan AD, Cook NR, Manson JE, Ridker PM, Buring JE. A randomized trial of low‐dose aspirin in the prevention of clinical type 2 diabetes in women. Diabetes Care 2009; 32: 3 – 8.en_US
dc.identifier.citedreferenceWei L, Fahey T, MacDonald TM. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10‐year follow‐up of outcome. Br J Clin Pharmacol 2008; 66: 110 – 6.en_US
dc.identifier.citedreferenceMant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493 – 503.en_US
dc.identifier.citedreferenceCannon CP, Rhee KE, Califf RM, et al. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). The American Journal of Cardiology 2010; 105: 445 – 52.en_US
dc.identifier.citedreferenceHealthcare Cost and Utilization Project. Available at: http://hcupnet.ahrq.gov. Accessed January 22, 2010.en_US
dc.identifier.citedreferenceRed Book. Montvale, NJ: Thomson Healthcare, Inc., 2009.en_US
dc.identifier.citedreferenceBriggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006.en_US
dc.identifier.citedreferenceCollet JP, Himbet F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000; 76: 257 – 8.en_US
dc.identifier.citedreferenceFerrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456 – 9.en_US
dc.identifier.citedreferenceEagle KA, Koelling TM, Montoye CK. Primer: implementation of guideline‐based programs for coronary care. Nat Clin Pract Cardiovasc Med 2006; 3: 163 – 71.en_US
dc.identifier.citedreferenceEllerbeck EF, Kresowik TF, Hemann RA, Mason P, Wiblin RT, Marciniak TA. Impact of quality improvement activities on care for acute myocardial infarction. Int J Qual Health Care 2000; 12: 305 – 10.en_US
dc.identifier.citedreferenceMarciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 1998; 279: 1351 – 7.en_US
dc.identifier.citedreferenceYang YX, Lewis JD, Epstein S, Metz DC. Long‐term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947 – 53.en_US
dc.identifier.citedreferenceLaine L. Proton pump inhibitors and bone fractures? The American Journal of Gastroenterology 2009; 104 ( Suppl 2 ): S21 – 6.en_US
dc.identifier.citedreferenceTargownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis‐related fractures. CMAJ 2008; 179: 319 – 26.en_US
dc.identifier.citedreferenceGulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community‐acquired pneumonia: a population‐based case‐control study. Arch Intern Med 2007; 167: 950 – 5.en_US
dc.identifier.citedreferenceGray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 2010; 170: 765 – 71.en_US
dc.identifier.citedreferenceTargownik LE, Lix LM, Leung S, Leslie WD. Proton‐pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896 – 904.en_US
dc.identifier.citedreferenceLeonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. The American Journal of Gastroenterology 2007; 102: 2047 – 56.en_US
dc.identifier.citedreferenceLowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile ‐associated disease: a population‐based study. Clin Infect Dis 2006; 43: 1272 – 6.en_US
dc.identifier.citedreferenceLinsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170: 772 – 8.en_US
dc.identifier.citedreferenceHo PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937 – 44.en_US
dc.identifier.citedreferenceAbraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010; 122: 2619 – 33.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2011.04707.x.pdf
Size:
246.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.